EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Percentage of free to total PSA as a biomarker of survival in metastatic castration‐resistant prostate cancer

Andrew W Silagy iD, Dixon T S Woon, Louise Kostos, Rui Bernardino, Ting W Yiu iD, Marian S Wettstein, Hanan Goldberg iD, Jaime O Herrera-Cáceres, Hina Shiakh, Gregory Nason, Alexandre Zlotta, Eleftherios Diamantis und 2 weitere

BJU International · 2025

DOI: 10.1111/bju.16751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Andrew W Silagy und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Austin Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Prostate-Specific Antigen, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To analyse whether the percentage of free to total prostate‐specific antigen (%fPSA) is a prognostic biomarker in metastatic castration‐resistant prostate cancer (mCRPC), as novel studies suggest an elevated %fPSA is associated with adverse oncological outcomes for men with biochemical recurrence of prostate cancer. Patients and Methods A biobank prospectively collated at mCRPC diagnosis was analysed for %fPSA. Clinicopathological characteristics, systemic therapies and survival outcomes were recorded. Patients were stratified by a %fPSA cut‐off of 15%. Cox proportional hazard models evaluated whether %fPSA was associated with overall survival (OS) and cancer‐specific survival (CSS) across the cohort and by treatment.

Results

A total of 254 patients analysed with newly diagnosed mCRPC: 161 (63%) men having a %fPSA ≥15%. The median follow‐up was 25.6 months. The median cohort OS and CSS was 39.6 and 43.8 months, respectively. Patients with a %fPSA ≥15% had lower median PSA level (31.30 vs 50.80 ng/mL; P = 0.007) and otherwise comparable clinicopathological and treatment profiles to men with a %fPSA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantProstate-Specific AntigenBiomarkers, TumorHumansMaleAgedMiddle AgedPrognosisProspective StudiesAged, 80 and overNeoplasm Metastasis

Stichwörter der Autor:innen

PSAbiomarkermetastasesoncologyprostate cancersurvival

Substanzen

Prostate-Specific AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Austin Health, Melbourne, Victoria, Australia.
  • Department of Surgery, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.
  • Division of Urology, University of Toronto, Toronto, Canada.
  • Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Urology Department, Upstate Medical University, Syracuse, NY, USA.

ORCID-Profile: Andrew W Silagy, Ting W Yiu, Hanan Goldberg

Zitieren

APA

Silagy, A. W., Woon, D. T. S., Kostos, L., Bernardino, R., Yiu, T. W., Wettstein, M. S., Goldberg, H., Herrera-Cáceres, J. O., Shiakh, H., Nason, G., Zlotta, A., Diamantis, E., Bolton, D., & Fleshner, N. (2025). Percentage of free to total PSA as a biomarker of survival in metastatic castration‐resistant prostate cancer. BJU International. https://doi.org/10.1111/bju.16751

Vancouver

Silagy AW, Woon DTS, Kostos L, Bernardino R, Yiu TW, Wettstein MS, et al. Percentage of free to total PSA as a biomarker of survival in metastatic castration‐resistant prostate cancer. BJU International. 2025. doi:10.1111/bju.16751

BibTeX
@article{Silagy2025,
  author = {Silagy, Andrew W and Woon, Dixon T S and Kostos, Louise and Bernardino, Rui and Yiu, Ting W and Wettstein, Marian S and Goldberg, Hanan and Herrera-Cáceres, Jaime O and Shiakh, Hina and Nason, Gregory and Zlotta, Alexandre and Diamantis, Eleftherios and Bolton, Damien and Fleshner, Neil},
  title = {Percentage of free to total PSA as a biomarker of survival in metastatic castration‐resistant prostate cancer},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16751}
}
Kostenlos starten →